Docoh
Loading...

LABP Landos Biopharma

News

From Benzinga Pro
80 Biggest Movers From Yesterday
17 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
53 Stocks Moving In Tuesday's Mid-Day Session
16 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss.
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021
16 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
SVB Leerink Downgrades Landos Biopharma to Market Perform, Lowers Price Target to $16
16 Nov 21
News, Downgrades, Price Target, Analyst Ratings
SVB Leerink analyst Thomas Smith downgrades Landos Biopharma (NASDAQ:LABP) from Outperform to Market Perform and lowers the price target from $20 to $16.
Landos Biopharma Q3 EPS $(0.32)
15 Nov 21
Earnings, News
Landos Biopharma (NASDAQ:LABP) reported quarterly losses of $(0.32) per share.
Landos Biopharma Announces FDA Clearance Of IND For LABP-104 For Treatment Of Rheumatoid Arthritis
2 Nov 21
News, FDA
Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases,
Watch Brilliant Earth, Landos Biopharma, Decibel Therapeutics Following TipRanks Article '3 "Strong Buy" Small-Cap Stocks With Plenty of Upside'
28 Oct 21
Media, Trading Ideas
https://www.tipranks.com/news/article/159057-2
Landos Biopharma Announces First Subject Dosed In A Phase 1 Study Of LABP-104 For Systemic Lupus Erythematosus
28 Oct 21
Biotech, News, FDA, General
Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases,
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
20 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Craig-Hallum Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $45
20 Oct 21
News, Price Target, Initiation, Analyst Ratings
Craig-Hallum analyst Robin Garner initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $45.
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
HC Wainwright & Co. Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $50
19 Oct 21
News, Price Target, Initiation, Analyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $50.
Landos Biopharma Announces FDA Clearance Of Its IND For LABP-104 For The Treatment Of Systemic Lupus Erythematosus
11 Oct 21
News, FDA
Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases,
Landos Biopharma Announces Publication In Scientific Reports Of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential In Models Of Psoriasis And Further Validating The LANCL2 Mechanism
6 Oct 21
News
Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases,
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
JonesTrading Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $39
23 Sep 21
News, Price Target, Initiation, Analyst Ratings
JonesTrading analyst Prakhar Agrawal initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $39.
Landos Biopharma To Collaborate On A Phase 2 Study Of Omilancor In Crohn's Disease With The Icahn School Of Medicine At Mount Sinai
20 Sep 21
News, Contracts
Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund

Press releases

From Benzinga Pro